•  
  •  
  •  
  •  

2026-05-23 15:10:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Bajaj Broking Weekly FII and DII Commentary for 23rd May 2026
  • TCC Concept Ltd delivers strong FY26 Growth
  • Gokaldas Exports consolidated FY26 Total Income up by 4% YoY
  • Trigyn Technologies Ltd - Result Highlights for Q4, FY26
  • Excelsoft Technologies Reports Strong Q4 & FY26 Performance

Keywords Selected:  DrReddysLaboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 8
  • Dr. Reddys Laboratories Ltd consolidated Q4 FY2025-26 PAT slides to Rs. 220.1 crores
  • Dr. Reddy's and Nestlé Health Science strengthens presence in diabetes & obesity nutrition space with Celevida® GLP+ launch
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India
  • Dr Reddys Laboratories Ltd consolidated Q3 FY2025-26 PAT drops to Rs. 1209.8 crores
  • Dr. Reddy's Laboratories announces Science-Based Net Zero Climate Targets
  • Immutep and Dr. Reddy's Enter Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
  • Dr. Reddy's receives European Commission Approval for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®
  • Dr Reddys Laboratories Ltd reports Rs. 1437.2 crores consolidated PAT in Q2FY26
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for AVT03 - denosumab
  • Dr. Reddy's launches novel molecule 'Tegoprazan' in India
  • Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda®
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy's Laboratories
  • Dr. Reddy’s Laboratories Ltd Q3 FY2025 consolidated PAT higher at Rs. 1413.3 crores
  • Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
  • IPO-bound Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
  • Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025
  • Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma
  • Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
  • Dr. Reddy's Laboratories Ltd receives order from COFEPRIS

Latest Post

  • Bajaj Broking Weekly FII and DII Commentary for 23rd May 2026
  • TCC Concept Ltd delivers strong FY26 Growth
  • Gokaldas Exports consolidated FY26 Total Income up by 4% YoY
  • Trigyn Technologies Ltd - Result Highlights for Q4, FY26
  • Excelsoft Technologies Reports Strong Q4 & FY26 Performance


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025